{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NovoTTF",
    "query": {
      "intervention": "NovoTTF"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 11,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=NovoTTF&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-11T16:24:05.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03501134",
      "title": "Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "NovoTTF",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2018-08-08",
      "completion_date": "2021-06-03",
      "has_results": false,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03501134"
    },
    {
      "nct_id": "NCT02343549",
      "title": "A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer of Brain and Nervous System"
      ],
      "interventions": [
        {
          "name": "NovoTTF100A",
          "type": "DEVICE"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2015-01",
      "completion_date": "2020-07-11",
      "has_results": true,
      "last_update_posted_date": "2022-11-03",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Charlotte, North Carolina",
      "locations": [
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343549"
    },
    {
      "nct_id": "NCT03194971",
      "title": "NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Tumor samples from patients treated with TTFields at initial diagnosis.",
          "type": "OTHER"
        },
        {
          "name": "Tumor samples from patients treated with TTFields at tumor recurrence.",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-06-01",
      "completion_date": "2023-06-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03194971"
    },
    {
      "nct_id": "NCT02663271",
      "title": "TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme",
        "Glioblastoma",
        "Malignant Glioma",
        "GBM"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Optune",
          "type": "DEVICE"
        },
        {
          "name": "Brain MRI",
          "type": "OTHER"
        },
        {
          "name": "Quality of Life Questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2016-12-19",
      "completion_date": "2021-06-11",
      "has_results": true,
      "last_update_posted_date": "2022-06-23",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 2,
      "location_summary": "Gainesville, Florida • St Louis, Missouri",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02663271"
    },
    {
      "nct_id": "NCT02903069",
      "title": "Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "MRZ",
          "type": "DRUG"
        },
        {
          "name": "TMZ",
          "type": "DRUG"
        },
        {
          "name": "RT",
          "type": "RADIATION"
        },
        {
          "name": "Optune",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2016-08-17",
      "completion_date": "2021-01-25",
      "has_results": false,
      "last_update_posted_date": "2021-04-19",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 6,
      "location_summary": "La Jolla, California • Orange, California • Santa Monica, California + 3 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02903069"
    },
    {
      "nct_id": "NCT02367482",
      "title": "Tryptophan Metabolism in Human Brain Tumors-Novocure",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2014-07",
      "completion_date": "2023-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-20",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02367482"
    },
    {
      "nct_id": "NCT01894061",
      "title": "NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NovoTTF-l00A",
          "type": "DEVICE"
        },
        {
          "name": "Quality of Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2013-09-18",
      "completion_date": "2019-07-01",
      "has_results": true,
      "last_update_posted_date": "2025-02-17",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 3,
      "location_summary": "Cincinnati, Ohio • Cleveland, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894061"
    },
    {
      "nct_id": "NCT03405792",
      "title": "Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Glioblastoma, WHO Grade IV"
      ],
      "interventions": [
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        },
        {
          "name": "Optune System",
          "type": "DEVICE"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2018-02-23",
      "completion_date": "2027-12",
      "has_results": true,
      "last_update_posted_date": "2026-02-06",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03405792"
    },
    {
      "nct_id": "NCT03353896",
      "title": "NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Anaplastic Oligodendroglioma",
        "Oligoastrocytoma",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Wear novoTTF-200A",
          "type": "DEVICE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2017-12-15",
      "completion_date": "2020-12-08",
      "has_results": false,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03353896"
    },
    {
      "nct_id": "NCT03477110",
      "title": "Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "NovoTTF-200A Device",
          "type": "DEVICE"
        },
        {
          "name": "Tumor Treating Fields Therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2018-05-04",
      "completion_date": "2024-01-26",
      "has_results": false,
      "last_update_posted_date": "2025-05-15",
      "last_synced_at": "2026-09-11T16:24:05.887Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03477110"
    }
  ]
}